Valeant Pharmaceuticals International Inc (NYSE:VRX)(TSX:VRX) stated on Thursday that it plans to pay down another USD200m of its senior secured term loans with cash on hand.
Following the repayment of debt next week, the company will have reduced its debt, in aggregate, by more than USD6.7bn since the end of Q1 2016.
In conjunction, the company's total long-term debt will be about USD25.5bn.
The specialist pharmaceutical company develops, manufactures and markets a broad range of pharmaceutical products in dermatology, gastrointestinal disorders, eye health, neurology and branded generics.
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Zentiva announces sale from Advent to GTCR
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions